%0 Journal Article
%T HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt<sup>®</sup>)
%A M. C. O. Ezeibe
%A B. L. Salako
%A F. I. O. Onyeachonam
%A A. David
%A O. O. Aina
%A E. Herbertson
%A M. E. Sanda
%A I. J. Ogbonna
%A E. Kalu
%A N. U. Njoku
%A M. I. Udobi
%A C. A. Akpan
%J World Journal of AIDS
%P 141-148
%@ 2160-8822
%D 2020
%I Scientific Research Publishing
%R 10.4236/wja.2020.102012
%X In verifying antiretroviral efficacy of a Nigerian broad spectrum
antiviral medicine (Antivirt<sup>®</sup>), the
Nigerian Institute of Medical Research certified it safe by toxicological test
on laboratory animals, before commencing treatment of three HIV/AIDS patients
whose viral loads varied widely (millions, hundreds of thousands and
thousands). To overcome errors associated with such wide differences in
subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month
of the Antivirt<sup>®</sup>-treatment, means of ranked viral loads of the
patients significantly (P ¡Ü 0.05) increased from 10.00 ¡À 7.21 to 11.30 ¡À 5.51 (-41.03% infection-reduction rate) instead of
reducing. From second month of the trial, their viral loads started to reduce,
continuously, so that their infection-reduction rates have been increasing from
that -41.03%, to -38.22% in the second month; 23.98% in the third month; 31.76% in the fourth month and
64.12% after the fifth month.
%K Antivirt<
%K sup>
%K &
%K #174
%K <
%K /sup>
%K Opposite Charges¡¯ Electrostatic Attraction
%K Continuous Depletion Of HIV-Infection Loads
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=101235